Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?

Shares of Recursion Pharmaceuticals (RXRX) have gained 4% over the past four weeks to close the last trading session at $7.26, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$9.29 indicates a potential upside of 28%.The average comprises seven short-term price targets ranging from a low of $6 to a high of$11, with a standard deviation of $1.70. While the lowest estimate indica ...